Ehsan Ghorani

8PUBLICATIONS
66CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersTumour immunologyHaematological tumoursCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 15, 2026
FasL-mediated death of activated intratumoral T cells drives secondary resistance to cancer immunotherapy.

|May 06, 2026
Malignant Adult Ovarian Germ Cell Tumors: An International Multicenter Study to Identify Relevant Prognostic Risk Factors for Stage IC and Beyond.

|Nov 22, 2023
Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade.

Annapaola Mariniello, Tahseen H Nasti, Daniel Y Chang

|Mar 01, 2021
CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity.

Isabelle Solomon, Maria Amann, Anne Goubier

|Aug 18, 2020
The T cell differentiation landscape is shaped by tumour mutations in lung cancer.

Ehsan Ghorani, James L Reading, Jake Y Henry

|Jun 05, 2020
Publisher Correction: Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer.

Kroopa Joshi, Marc Robert de Massy, Mazlina Ismail

Pageof 2

Frequent Collaborators

6 joint publications

Sergio A Quezada

4 joint publications

Imran Uddin

3 joint publications

Sine R Hadrup

3 joint publications

Felipe Gálvez-Cancino